Examination of the human kinome for novel genome-specific therapeutic targets in triple-negative breast cancer (TNBC)

Investigator(s): George Sledge, M.D.
Lead Organization: Stanford University
Grant Mechanism: SAB Grants
Grant ID: SAB0800003

Public Abstract:
Measuring circulating tumor cells (CTCs) in patients with advanced breast cancer is a currently available clinical test, but one whose potential to affect patient outcome has been limited. While we do a good job of counting CTCs with existing technology, and while CTC counts tell us something about treatment response and ultimate prognosis, these alone do not "move the needle" with regard to breast cancer treatment and outcome. New approaches are needed to fulfill the potential of CTC evaluation. We are evaluating two novel, locally created technologies to evaluate CTCs. The first has the potential to measure CTCs noninvasively with great precision. The second has the potential to be used to measure the effects of targeted therapies on breast cancer cells, providing an early read-out on benefit and appropriate dosing of new targeted agents.